Can people with nonsevere major depression benefit from antidepressant medication?

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 518-525

  Stewart, Jessica A ^a   Deliyannides, Deborah A ^b   Hellerstein, David J ^b   McGrath, Patrick J ^b   Stewart, Jonathan W ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIANSERIN; PHENELZINE;

ADULT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DSM-III; DSM-III-R; FEMALE; HAMILTON SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; SELF REPORT; TREATMENT RESPONSE;

EID: 84860550796     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06760     Document Type: Review

References (35)

1. Moncrieff J. Are antidepressants overrated? a review of methodological problems in antidepressant trials. J Nerv Ment Dis. 2001;189(5):288-295. doi:10.1097/05053-201050-03 PubMed (Pubitemid 32448650)
2. Healy D. The three faces of the antidepressants: a critical commentary on the clinical-economic context of diagnosis. J Nerv Ment Dis. 1999;187(3):174-180. doi:10.1097/05053-19030-07 PubMed (Pubitemid 29136339)
3. Fisher S, Greenberg RP. How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis. 1993;181(6):345-350. doi:10.1097/05053-193060-02 PubMed (Pubitemid 24259604)
4. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53. doi:10.101/jama.209.1943 PubMed
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
6. Tedlow J, Fava M, Uebelacker L, et al. Outcome definitions and predictors in depression. Psychother Psychosom. 1998;67(4-5):266-270. doi:10.159/01290 PubMed (Pubitemid 28386472)
7. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45. doi:10.1371/journal.pmed.05045 PubMed
8. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22(1):40-45. doi:10.1097/04714-202020-07 PubMed (Pubitemid 34101291)
9. Silva de Lima M, Moncrieff J, Soares B. Drugs versus placebo for dysthymia (review). The Cochrane Collaboration. John Wiley & Sons, Hoboken, New Jersey, 2009 http://www.thecochranelibrary.com.
10. Stewart JW, Quitkin FM, Klein DF. The pharmacotherapy of minor depression. Am J Psychother. 1992;46(1):23-36. PubMed
11. Stewart JW, McGrath PJ, Quitkin FM. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Am J Psychiatry. 1992;149(5):615-619. PubMed
12. Kocsis JH, Frances AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry. 1988;45(3):253-257. PubMed (Pubitemid 18081674)
13. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry. 1993;150(8):1169-1175. PubMed (Pubitemid 23218896)
14. Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res. 2005;39(2):145-150. doi:10.1016/j.jpsychires.204.06.05 PubMed (Pubitemid 39602638)
15. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35(7):837-844. PubMed (Pubitemid 9076798)
16. Williams JB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-III. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1985.
17. Williams JB, Spitzer RL Gibbon M, et al. Structured Clinical Interview for DSM-III-R. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1987.
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
19. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782. PubMed (Pubitemid 9064061)
20. Stewart JW, McGrath PJ, Liebowitz MR, et al. Treatment outcome validation of DSM-III depressive subtypes: clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry. 1985;42(12):1148-1153. PubMed (Pubitemid 16191173)
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
22. McGrath PJ, Rabkin JG, Stewart JW, et al. Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiology. 1985;14(3):128-132. doi:10.159/018218 PubMed (Pubitemid 16154550)
23. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45(2):129-137. PubMed (Pubitemid 18052843)
24. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry. 1988;145(3):306-311. PubMed (Pubitemid 18078309)
25. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry. 1990;47(10):935-941. PubMed (Pubitemid 20348481)
26. Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry. 1989;46(9):787-793. PubMed (Pubitemid 19233227)
27. McGrath PJ, Stewart JW, Janal MN, et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157(3):344-350. doi:10.176/api.ajp.157.3.34 PubMed (Pubitemid 30145918)
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
30. Guy W. ECDEU Assessment Manual of Psychopharmacology-Revised. Rockville, MD: U.S. Department of Health, Education and Welfare; 1976.
31. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. doi:10.1016/S06-323(02)0186-8 PubMed (Pubitemid 37289444)
32. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571. PubMed
33. Derogatis LR. SCL-9OR Administration, Scoring, and Procedures Manual. Baltimore, MD: Clinical Psychometric Research; 1977.
34. Marshall RJ. The pharmacology of mianserin - an update. Br J Clin Pharmacol. 1983;15(suppl 2):263S-268S. PubMed
35. Horder J, Matthews P, Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacology. 2010, Jun 22 [Epub ahead of print] PubMed jop.sagepub.com.